Pioglitazone PCD Pharma Franchise Company

Cafoli Lifecare is a WHO-GMP certified Pioglitazone PCD pharma franchise company offering 10 Pioglitazone formulations across Tablets. Every batch is manufactured in DCGI-approved, WHO-GMP compliant facilities and supplied to franchise partners on a monopoly basis with full promotional backing.

What is Pioglitazone?

Pioglitazone is an oral anti-diabetic agent of the thiazolidinedione (TZD) class. It is an agonist of the peroxisome proliferator-activated receptor gamma (PPAR-gamma), and by activating this nuclear receptor in adipose tissue, muscle and liver it improves insulin sensitivity and reduces hepatic glucose output. It is used as an adjunct to diet and exercise in type 2 diabetes mellitus, usually alongside metformin or a sulfonylurea. See the compound record on PubChem.

Pioglitazone Range Available for Franchise

Our Pioglitazone portfolio comprises 10 formulations available in the following dosage forms: Tablets. Brand names, compositions, packing and net rates are shared on request with partners holding a valid Drug License. Contact us for the current Pioglitazone price list and stock position.

Therapeutic Applications of Pioglitazone

Pioglitazone is indicated for glycaemic control in type 2 diabetes mellitus, particularly in insulin-resistant patients, and is commonly supplied in fixed-dose combinations with metformin and glimepiride. It is a prescription-only medicine requiring periodic monitoring of liver function, fluid retention and cardiac status. Prescribers are chiefly diabetologists and endocrinologists, followed by consulting physicians and general practitioners managing chronic diabetes.

Why Pioglitazone is a High-Potential Molecule for Distributors

India carries one of the largest type 2 diabetes populations in the world, and insulin resistance — the specific defect pioglitazone targets — is a defining feature of the Indian metabolic phenotype. That gives the molecule a clear clinical niche even as newer classes enter the market: it remains one of the few genuinely low-cost insulin sensitisers, and prescribers use it as a value add-on when patients cannot afford DPP-4 inhibitors or SGLT2 agents. Commercially, diabetes is lifelong therapy, so every conversion becomes a monthly repeat order for years. Its wide use in dual and triple fixed-dose combinations also gives a distributor several SKUs from a single molecule.

Why Choose Cafoli Lifecare for Your Pioglitazone Franchise

Cafoli Lifecare works with over 1000+ franchise partners across India. Partners receive monopoly rights for their district or territory, WHO-GMP certified and DCGI-approved products, complete promotional inputs (visual aids, MR bags, samples, prescription pads, gifts), transparent net rates, and dependable dispatch. Our documentation and stock support are built for distributors who want to scale without operational friction.

References

1. PubChem — Pioglitazone compound record (NIH / NCBI)
2. MedlinePlus — Pioglitazone drug information (US National Library of Medicine)
3. PubMed — clinical literature on Pioglitazone